CHMP Backs Factor Xa Reversal Agent Andexanet (Ondexxya) CHMP Backs Factor Xa Reversal Agent Andexanet (Ondexxya)

Andexanet alfa, approved in the United States in 2018, would be the first drug approved for reversing major bleeds with the factor Xa inhibitors apixaban and rivaroxaban in Europe.International Approvals
Source: Medscape Pathology Headlines - Category: Pathology Tags: Cardiology News Alert Source Type: news